PharmaCyte Biotech, Inc. (NASDAQ: PMCB), today announced the results of an additional, more finely detailed, analysis of the integration site of the cytochrome P450 2B1 gene from the augmented HEK293 cell clone that is used in PharmaCyte’s pancreatic cancer product candidate known as CypCaps™.
February 22, 2022
· 4 min read